Tag Archives: taps

Celgene taps Bristol-Myers salesforce to bolster key blood cancer launches

SAN FRANCISCO—After agreeing last year to swallow Celgene for a whopping $ 74 billion, Bristol-Myers Squibb trumpeted the potential of pairing its solid-tumor expertise with Celgene’s hematology expertise to create a leading cancer drugmaker. But the legacy BMS business had some hematology expertise of its own—and Celgene’s taking advantage, said Nadim Ahmed, the now-combined company’s… Read More »